Education
About Us
Working with TipRanks
Follow Us
Reckitt Benckiser Group (RBGLY)
OTHER OTC:RBGLY
RBGLY Stock Chart & Stats
$15.72
$0.07(0.58%)
At close: 4:00 PM EST
$15.72
$0.07(0.58%)
Day’s Range― - ―
52-Week Range$12.61 - $17.61
Previous CloseN/A
VolumeN/A
Average Volume (3M)20.41K
Market Cap
$45.70B
Enterprise Value$41.02B
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$8.42B
Price to Earnings (P/E)12.6
Beta0.18
Next Earnings
Jul 29, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield3.33%
Share Statistics
EPS (TTM)0.49
Shares Outstanding3,223,868,200
10 Day Avg. Volume0
30 Day Avg. Volume20,409
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.08
Price to Sales (P/S)2.83
P/FCF Ratio22.79
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.90
Enterprise Value/Gross Profit4.77
Enterprise Value/Ebitda8.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.94
Revenue Forecast (FY)$17.13B
Bulls Say, Bears Say
Bulls Say
Innovation & Product WinsSustained R&D and successful new product launches (Durex Intensity, Mucinex NDA) strengthen brand premiumization and category expansion. Durable innovation capability supports long-term pricing power, shelf relevance and higher-margin product mix, aiding revenue resilience across cycles.
Emerging Markets OutperformanceHigh growth and expanding margins in Emerging Markets create durable revenue diversification and a margin tailwind. Strong execution in China and India plus online penetration reduces reliance on slower developed markets and supports sustainable top-line and profit expansion over multiple years.
Productivity Program Delivering SavingsMeaningful fixed-cost reduction from a structured productivity program enhances operating leverage and funds targeted brand investment. If sustained, these efficiency gains can offset cost pressures, protect margins and improve cash generation through the 2–3 year execution horizon.
Bears Say
Elevated Leverage And Near-term RiseHigher leverage reduces financial flexibility to fund investment or weather demand shocks. A rise toward ~2.5x increases refinancing and interest-rate sensitivity, constraining capital allocation and making consistent cash conversion critical to avoid credit pressure over the medium term.
Declining Free Cash Flow ConversionLower FCF conversion, driven by elevated CapEx and restructuring cash costs, weakens the firm's ability to delever and sustain buybacks/dividends. Persistent declines would pressure liquidity and limit strategic flexibility, magnifying risks from existing leverage and investment commitments.
Developed-market Demand Softness & Share LossSoftness in Europe and seasonal OTC alongside significant CMU share losses signal structural competitive and demand challenges in core developed markets. Sustained share erosion would pressure organic growth and force higher promotional spend, undermining margins and long-term brand strength.
Reckitt Benckiser Group News
RBGLY FAQ
What was Reckitt Benckiser Group’s price range in the past 12 months?
Reckitt Benckiser Group lowest stock price was $12.61 and its highest was $17.61 in the past 12 months.
What is Reckitt Benckiser Group’s market cap?
Reckitt Benckiser Group’s market cap is $45.70B.
When is Reckitt Benckiser Group’s upcoming earnings report date?
Reckitt Benckiser Group’s upcoming earnings report date is Jul 29, 2026 which is in 136 days.
How were Reckitt Benckiser Group’s earnings last quarter?
Currently, no data Available
Is Reckitt Benckiser Group overvalued?
According to Wall Street analysts Reckitt Benckiser Group’s price is currently Overvalued.
Does Reckitt Benckiser Group pay dividends?
Reckitt Benckiser Group pays a Quarterly dividend of $0.227 which represents an annual dividend yield of 3.33%. See more information on Reckitt Benckiser Group dividends here
What is Reckitt Benckiser Group’s EPS estimate?
Reckitt Benckiser Group’s EPS estimate is 0.44.
How many shares outstanding does Reckitt Benckiser Group have?
Reckitt Benckiser Group has 3,223,868,200 shares outstanding.
What happened to Reckitt Benckiser Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Reckitt Benckiser Group?
Currently, no hedge funds are holding shares in RBGLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Reckitt Benckiser Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
RBGLY Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.22%
12-Months-Change
Fundamentals
Return on Equity
17.21%
Trailing 12-Months
Asset Growth
1.06%
Trailing 12-Months
Company Description
Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom, the United States, China, India, and internationally. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands. It also provides analgesics; sore throat medications; and hair removal products under the Nurofen, Strepsils, and Veet brands. In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; fabric washing; and other hygiene products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as analgesics, adult nutrition products, iron-fortified hypoallergenic baby formula, products for joint issues, and infant and toddler nutrition products, as well as vitamins, minerals, and supplements under the Biofreeze, Airborne, Mead Johnson, Move Free, Enfamil, and Nutramigen brands. Further, it provides probiotics, sore throat pain relief products, Omega products, brain health support products, cleaning and carpet cleaning products, septic tank system treatment products, cough syrups, plant-based laundry products, probiotics, and lubricants under the Digestive Advantage, Cepacol, MegaRed, Neuriva, Easy-Off, RID-X, Delsym, Botanical Origin, Bodi-Ome, and K-Y brands. The company was founded in 1819 and is headquartered in Slough, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---